New data reveals 1 in 85 people worldwide will suffer from Alzheimer’s disease by 2050. At a conference in Washington DC drug companies ranging from Glaxo (GSK) to Eli Lilly (LLY) are presenting data on their new drugs to combat this devastating disease. Early word suggests a new drug from Medivation (MDVN) is showing promise in trials.
CNBC Pharmaceutical Reporter Mike Huckman joins the guys for this conversation.
Mike says a trio of biotech stocks moved on the data coming out of the conference. MDVN is testing an anti-histamine from Russia on Alzheimer’s patients and early results suggest the drug might stabilize and perhaps improve the mental acuity of patients.